Literature DB >> 2434407

The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen.

E S Cibas, J M Corson, G S Pinkus.   

Abstract

The immunohistochemical profile (i.e., carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, human milk fat globule-derived antigen, and mucin) of paraffin-embedded cell blocks of 20 malignant effusions from patients with malignant mesothelioma was compared with that of 39 malignant effusions from patients with metastatic adenocarcinoma to determine whether these markers distinguished between these tumor types. Twenty-three adenocarcinomas (59 per cent) stained for mucin. Immunoreactivity for carcinoembryonic antigen (CEA) was observed in 28 adenocarcinomas (72 per cent). All were immunoreactive for keratin proteins, and 29 adenocarcinomas (74 per cent), including seven that were mucin and CEA negative and exhibited a "peripheral predominant" staining pattern for keratin proteins. By contrast, none of the mesotheliomas stained for mucin or for CEA, and, although all were immunoreactive for keratin proteins, none demonstrated a peripheral predominant pattern of staining. Epithelial membrane antigen and milk fat globule-derived antigen were identified in the majority of both mesotheliomas and adenocarcinomas. Neither staining intensity nor pattern of reactivity of these markers clearly distinguished the tumors. This study of cell blocks of serous effusions suggests that staining for mucin, immunoreactivity for carcinoembryonic antigen, and a peripheral predominant pattern of reactivity for keratin proteins represent highly characteristic markers of adenocarcinomas, which identify the majority of these tumors (38 of 39) and allow their distinction from malignant mesotheliomas.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434407     DOI: 10.1016/s0046-8177(87)80196-x

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  Evaluation of impact of immunocytochemical techniques in cytological diagnosis of neoplastic effusions.

Authors:  A Linari; G Bussolati
Journal:  J Clin Pathol       Date:  1989-11       Impact factor: 3.411

2.  HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.

Authors:  A D Kennedy; G King; K M Kerr
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

3.  Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.

Authors:  T Kawai; S D Greenberg; L D Truong; C A Mattioli; M Klima; J L Titus
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

4.  Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1.

Authors:  M L Warnock; A Stoloff; A Thor
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

5.  The value of anticarcinoembryonic antigen, human milk factor globulin, and antikeratin antibodies in differentiating mesothelioma from lung carcinoma.

Authors:  V M Joglekar; D Oliver; M Harris
Journal:  Br J Ind Med       Date:  1991-01

6.  ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.

Authors:  C J O'Hara; J M Corson; G S Pinkus; R A Stahel
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

7.  Establishment and characterization of a new human colon adenocarcinoma cell line: BCS-TC2.

Authors:  J Turnay; N Olmo; J G Gavilanes; J Benitez; M A Lizarbe
Journal:  Cytotechnology       Date:  1990-01       Impact factor: 2.058

8.  Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.

Authors:  C S Kortsik; P Werner; N Freudenberg; J C Virchow; C Kroegel; M Pott; H Matthys
Journal:  Lung       Date:  1995       Impact factor: 2.584

Review 9.  Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review.

Authors:  S K Mohanty; P Dey
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

Review 10.  Serous cavity metastasis: Evaluation of unknown primary.

Authors:  Nirag Jhala; Aileen Arriola; Liron Pantanowitz
Journal:  Cytojournal       Date:  2022-03-19       Impact factor: 2.345

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.